Salts and solid form of a BTK inhibitor
AssigneePrincipia Biopharma Inc.
InventorsMohammad Reza Masjedizadeh, Steven Gourlay
Life of this patent
Estimating the term…
Abstract
Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
Claims4
A method of treating a disease or disorder in a mammal, the disease or disorder selected from:
- acute flares of an autoimmune and/or inflammatory disease selected from at least one of IgA nephropathy, inflammatory bowel disease ulcerative colitis arthritis, lupus, Lupus Nephritis, osteoarthritis Still's disease, juvenile arthritis, diabetes, myasthenia gravis, granulomatosis with polyangiitis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, Sjogren's dry eye, and non-Sjogren's-dry eye disease,
- comprising administering to the mammal a pharmaceutical composition comprising
- a compound selected from the (E) isomer, the (Z) isomer, and a mixture of (E) and (Z) isomers of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile;
- or
- a pharmaceutically acceptable salt of any of the foregoing compounds.
Dependencies are inferred from the claim text.